An Investigator-Sponsored Phase 1/2 Study of Selinexor (KPT-330) and Docetaxel as Second Line Therapy in Patients With Relapsed Squamous Cell Lung Cancer
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Selinexor (Primary) ; Docetaxel
- Indications Lung cancer
- Focus Therapeutic Use
- 29 Oct 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov reocord.
- 04 Sep 2015 New trial record